GMAB News and Press, Genmab A/S

2026-03-16 10:47:04 ET As the U.S.-Iran conflict enters its 16th day, persistent geopolitical friction and energy shocks have triggered deep volatility across U.S. benchmarks. This broad-based retreat has pushed several key sectors into technically oversold territory.... Read the full...

2026-03-11 14:52:24 ET Genmab A/S (GMAB) Barclays 28th Annual Global Healthcare Conference March 11, 2026 1:30 PM EDT... Read the full article on Seeking Alpha For further details see: Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

2026-03-11 08:18:00 ET The following segment was excerpted from the Harbor Health Care ETF Q4 2025 Commentary . ... Read the full article on Seeking Alpha For further details see: Harbor Health Care ETF Q4 2025 Portfolio Review

2026-02-20 09:24:40 ET More on Novo Nordisk Novo Nordisk Is Under Pressure - And Trading At A Discount Novo Nordisk: The Possible Upside Novo Nordisk: How Low Is Too Low? (Downgrade, Technical Analysis) Novo Nordisk board proposes DKK 7.95 final dividend for ...

2026-02-18 06:15:10 ET H.C. Wainwright analyst issues BUY recommendation for GMAB on February 18, 2026 11:08AM ET. The previous analyst recommendation was Buy. GMAB was trading at $30 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...

2026-02-17 23:53:12 ET More on Genmab Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript Genmab A/S 2025 Q4 - Results - Earnings Call Presentation Genmab: Darzalex Growth Fuels Rally, Upside Is Tight Genmab down after trial data for AbbVie-partnered Epkinly i...

2026-02-17 16:14:57 ET Genmab A/S (GMAB) Q4 2025 Earnings Call February 17, 2026 12:00 PM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Brad Bailey Anthony Pagano - Executive VP & CFO Tahamtan Ahmadi - Executive VP, Chief Me...

Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026. The full...

Iamgold Corporation (IAG) is expected to report $0.55 for Q4 2025 Bel Fuse Inc (BELFB) is expected to report $1.44 for Q4 2025 Beta Bionics Inc. (BBNX) is expected to report $-0.42 for Q4 2025 TPG RE Finance Trust Inc. (TRTX) is expected to report $0.25 for Q4 2025 CEVA Inc. (CEVA...

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. Equity-Insider.com   News Commentary   VANCOUVER, BC , Jan. 30, 2026 /CNW/ -- The oncology sector is underg...